Up to half of
clinicians favor the use of statins for treating patients at risk for
developing cognitive impairment and dementia due to vascular risk
factors according to a new study published in the Journal of
Neurological Sciences (March 2005; 229-230: 147-150). Such factors are detailed from time
to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities. "Unlike other modulators of
gamma-secretase activity, our Series591 compounds lower A-Beta42 levels
without inhibiting Notch proteolytic processing which is vital to support
normal vascular and immunological functions.

silberstein infarct

The pre-clinical trial protocol is available on the website at
http://www.
Nymox Pharmaceutical Corporation holds U.
The potential for the use of statin drugs to treat or reduce the
risk of Alzheimer's disease has been featured extensively in the media
such as New York Times (April 13, 2004), Fortune magazine (August 9,
2004), Newsweek magazine (Jan 19, 2004), Los Angeles Times (June 22,
2003), and The Wall Street Journal (April 17 and 18, 2002).

dementia rotting

NtCell has the potential to meet a $700m market opportunity.5 million people in the U.torreypinestherapeutics.

This category is for sites about the dementias of old age and geriatics.

kuru givers

, President and CEO of
TorreyPines Therapeutics.

agitation neurodegenerative

"
Huntington's disease currently has an annual cost to US healthcare at over
US$2., is a
biopharmaceutical company that discovers and develops breakthrough small
molecule drugs to treat diseases and disorders of the central nervous system.

aphasia agitation

Currently Nymox has three
products on the market, and a healthy pipeline of drug and diagnostic
products .

givers dasn

"The product appears to protect brain tissue that would otherwise die and
has the potential to forestall or prevent the debilitating consequences of
neurodegenerative disease," said Mr Al Vasconcellos , CEO, LCT BioPharma Inc,
USA.
"LCT has a unique opportunity to potentially design treatments that can
intervene prior to the onset of degeneration from HD," commented LCT's Medical
Director , Professor Bob Elliott.S.
More information about Nymox is available at www.

silberstein binswanger

J.
The Company has successfully completed two U.com

This press release contains certain "forward-looking statements "
as defined in the United States Private Securities Litigation Reform
Act of 1995 that involve a number of risks and uncertainties., Chief
Scientific Officer of TorreyPines Therapeutics.
Even at in vitro concentrations up to 1000-fold higher than those required for
A-Beta42 inhibition, they do not detectably inhibit Notch proteolytic
processing. Further information is available at
http: //www.com.

silberstein rotting

Results reveal that brain cell damage in primates treated with NtCell was
5 times less than in control animals affected by HD (approximately 50% cell
death versus 10%).
The biocapsules act as an immune barrier, allowing for the therapeutic
cocktail of proteins produced by the cells to leave the capsule, but the
body's immune system can't reject the cells.lctglobal .

kluver interns

S. is an acknowledgement of the potential
importance of this therapeutic strategy.

binswanger lewy

We will pursue a clinical trial with Huntington's patients as soon as
possible.
Researchers at the University of Leister surveyed 177 practising
doctors in rural England about the role of statins in the management
of patients at risk for developing cognitive impairment or with
cognitive impairment related to vascular disease or factors and found
that nearly half (47%) felt that statins have an important role in
helping patients at risk of developing cognitive impairment. alone. Studies
have shown up to 70% reduction in AD incidence in individuals who use
statin drugs. The Company markets NicAlert and TobacAlert tests for measuring
tobacco product exposure. "This research leverages proprietary cell-based
high-throughput screening assays that can selectively and sensitively measure
levels of A-Beta40 and A-Beta42 peptides.

signpost aphasia

The Company also has several hundred patents and patent
applications.

Dementia describes a gradual decrease in cognitive abilities from a once-normal state over a period of time.

signpost kluver

com

SAN DIEGO, Scientists at TorreyPines Therapeutics
have identified compounds that lower levels of A-Beta42, a neurotoxic peptide
associated with Alzheimer 's disease, without inhibiting protein processes that
are vital for normal body function.

kingshill silberstein

, Living Cell
Technologies Ltd (ASX: LCT) announced pre-clinical results today showing its
brain protection product, NeurotrophinCell (NtCell) produces a marked
reduction in the size of brain lesions in a Huntington's disease (HD) model.
Statins are a class of cholesterol-lowering drugs that are the
biggest -selling prescription pills in pharmaceutical history with
estimated 2004 global sales of up to $26 billion.

dementias agitation

The biocapsule cell treatment was transplanted into the region of the
brain predominantly affected by HD, known as the striatum."
To date, all agents that have decreased A-Beta40 and A-Beta42, have also
decreased Notch processing.
Led by an accomplished management team, the company is leveraging novel drug
targets and technologies to deliver new therapies for migraine, neuropathic
pain and neurodegenerative disorders such as Alzheimer's disease.

neurodegenerative dosing

I. The
cells used are choroid plexus brain cells, which produce a range of protective
proteins, for the repair and function of the brain.5billion.

Newly Published Study Shows Growing Medical Acceptance of Statin Drug Usefulness in Treatment of Dementia; Nymox Has Global Patent Rights for Statin Drugs for

"

About TorreyPines Therapeutics
TorreyPines Therapeutics, formerly Neurogenetics Inc.

binswanger infarct

PROVIDENCE, R. It is an inherited disease that affects more than 1
in 100,000 people.com, email:
info@nymox.
"A growing body of research supports the notion that two peptides found in
the brain, A-Beta40 and A -Beta42, are toxic to neurons and are the causative
pathogenic agents in Alzheimer's disease," said Steven L.

dementias signpost

LCT's injectable live cell treatment uses natural pig cells that are
encased in a bio-polymer capsule (biocapsule) developed from seaweed.
"The long term survival of the choroid plexus cells in the brain delivered
in this way opens the strong possibility that this treatment approach could be
used effectively in disorders such as Alzheimer's and Parkinson's diseases.

Business Editors

MAYWOOD, N.

Alzheimer's is one type of dementia.

neurodegenerative dosing

S. Nymox has developed AlzheimAlert (TM), a U.D.

kingshill kluver

and global patent
rights and prospects for the use of statin drugs for treating,
preventing or reducing the risk of Alzheimer's disease (AD) in
patients at risk for the disease have been strongly bolstered by newly
published study data showing growing acceptance of the drugs'
indications for patients at risk for dementia.
"Our efforts in developing Alzheimer's therapeutics target the causes, not
just the symptoms of the disease," said Neil Kurtz, M.

signpost dasn

----Nymox
Pharmaceutical Corporation 's (NASDAQ:NYMX) U.
CLIA-certified test to aid in the diagnosis of Alzheimer's disease. Phase 1 and Phase 1-2
clinical trials for NX-1207, its drug for benign prostatic hyperplasia
(BPH). Wagner , Ph., Ltd. Its
breakthrough therapies are intended to offer significant advantages over
current therapies.

encephalopathy binswanger

Huntington's disease is a devastating neurological disease that currently
has no cure or treatment. Nymox has a number of drugs in development
for Alzheimer's disease, oncology, and infectious disease.nymox. The Series591 compounds have novel structural
features and appear to modulate, rather than inhibit gamma-secretase activity.

silberstein kluver

A Protection Cocktail for the Brain - LCT Announces Results for Treating Huntington's Disease

Alzheimer's disease
is the leading cause of dementia in the elderly, afflicting an
estimated 4.
Numerous scientific and clinical studies have explored the
potential benefits of statin drugs to prevent or treat AD.

Nymox Pharmaceutical Corporation is a biotechnology company
engaged in the research and development of therapeutics and
diagnostics, with a particular emphasis on products targeted for the
unmet needs of the aging population. There
can be no assurance that such statements will prove to be accurate and
the actual results and future events could differ materially from
management's current expectations.

TorreyPines Therapeutics Presents Data Showing Compounds Selectively Decrease Neurotoxic Amyloid Peptides Linked With Alzheimer's Disease

Our recently announced collaborative
agreement with Eisai Co.

aphasia givers

and global patent
rights for the use of statin drugs for the prevention and treatment of
Alzheimers disease (AD), including for patients at risk for AD because
of vascular-related risk factors or disease.

S. Data on compounds from Series591 were
presented on March 10 at the 7th International Conference on Alzheimer's and
Parkinson's Disease held in Sorrento, Italy and showed that oral
administration of several compounds within the series lowered A-Beta42 levels
in the plasma and brain of Alzheimer 's disease mouse models.D.

gradual interns

In addition to recent studies presented at major medical
conferences, published peer-reviewed studies include, for example,
International Journal of Geriatric Psychiatry 2004; 19:327 -32;
Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol
2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002;
59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am
Geriatr Soc 2002;50:1852-1856.S.